

Michael Platten

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4668070/michael-platten-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

246 papers	18,207 citations	67 h-index	132 g-index
279 ext. papers	23,418 ext. citations	8.5 avg, IF	6.44 L-index

#	Paper	IF	Citations
246	An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. <i>Nature</i> , 2011 , 478, 197-203	50.4	1185
245	DNA methylation-based classification of central nervous system tumours. <i>Nature</i> , 2018 , 555, 469-474	50.4	992
244	Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2012 , 13, 707-15	21.7	792
243	Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 14948-53	11.5	690
242	Brain tumour cells interconnect to a functional and resistant network. <i>Nature</i> , 2015 , 528, 93-8	50.4	496
241	A vaccine targeting mutant IDH1 induces antitumour immunity. <i>Nature</i> , 2014 , 512, 324-7	50.4	481
240	Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. <i>Cancer Research</i> , 2012 , 72, 5435-40	50.4	456
239	Aryl hydrocarbon receptor control of a disease tolerance defence pathway. <i>Nature</i> , 2014 , 511, 184-90	50.4	436
238	Lomustine and Bevacizumab in Progressive Glioblastoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1954-1963	59.2	425
237	Actively personalized vaccination trial for newly diagnosed glioblastoma. <i>Nature</i> , 2019 , 565, 240-245	50.4	388
236	Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. <i>Nature Reviews Drug Discovery</i> , 2019 , 18, 379-401	64.1	352
235	SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. <i>Cancer Research</i> , 2004 , 64, 7954-61	10.1	347
234	Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. <i>Science</i> , 2005 , 310, 850-5	33.3	344
233	DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. <i>Lancet Oncology, The</i> , 2017 , 18, 682-694	21.7	336
232	MGMT testing--the challenges for biomarker-based glioma treatment. <i>Nature Reviews Neurology</i> , 2014 , 10, 372-85	15	316
231	ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. <i>Acta Neuropathologica</i> , 2015 , 129, 133-46	14.3	313
230	ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. <i>Acta Neuropathologica</i> , 2013 , 126, 443-51	14.3	239

229	Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors. <i>Frontiers in Immunology</i> , 2014 , 5, 673	8.4	232
228	Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. <i>Stem Cells</i> , 2009 , 27, 909-19	5.8	224
227	Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. <i>Acta Neuropathologica</i> , 2013 , 126, 907-15	14.3	211
226	Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3357-61	2.2	208
225	MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. <i>Clinical Cancer Research</i> , 2015 , 21, 2057-64	12.9	206
224	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. <i>Nature Reviews Clinical Oncology</i> , 2021 , 18, 170-186	19.4	204
223	IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. <i>Acta Neuropathologica</i> , 2015 , 129, 867-73	14.3	200
222	Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta. <i>Journal of Neuro-Oncology</i> , 2001 , 53, 177-85	4.8	195
221	Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. <i>Acta Neuropathologica</i> , 2015 , 130, 407-17	14.3	194
220	Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape. <i>Microscopy Research and Technique</i> , 2001 , 52, 401-10	2.8	190
219	Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. <i>Oncotarget</i> , 2014 , 5, 1038-51	3.3	189
218	Monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas. <i>Annals of Neurology</i> , 2003 , 54, 388-92	9.4	180
217	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2020 , 22, 1073-1113	1	178
216	Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. <i>Nature Medicine</i> , 2018 , 24, 1192-1203	50.5	174
215	Trial watch: IDO inhibitors in cancer therapy. <i>OncoImmunology</i> , 2014 , 3, e957994	7.2	166
214	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. <i>Acta Neuropathologica</i> , 2018 , 136, 153-166	14.3	162
213	Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study. <i>Lancet Oncology, The</i> , 2019 , 20, 728-740	21.7	160
212	Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. <i>Neurology</i> , 2013 , 81, 1515-22	6.5	160

211	Angiotensin II sustains brain inflammation in mice via TGF-beta. <i>Journal of Clinical Investigation</i> , 2010 , 120, 2782-94	15.9	157
210	Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. <i>Acta Neuropathologica</i> , 2016 , 131, 903-10	14.3	151
209	Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. <i>Acta Neuropathologica</i> , 2014 , 128, 561-71	14.3	148
208	Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. <i>Acta Neuropathologica</i> , 2018 , 136, 181-210	14.3	148
207	Secreted Frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells. <i>Oncogene</i> , 2000 , 19, 4210-20	9.2	138
206	MICA/NKG2D-mediated immunogene therapy of experimental gliomas. <i>Cancer Research</i> , 2003 , 63, 8996-9006	10.6	137
205	mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 409-14	11.5	126
204	New (alternative) temozolomide regimens for the treatment of glioma. <i>Neuro-Oncology</i> , 2009 , 11, 69-79	1	125
203	Transforming growth factors beta(1) (TGF-beta(1)) and TGF-beta(2) promote glioma cell migration via Up-regulation of alpha(V)beta(3) integrin expression. <i>Biochemical and Biophysical Research Communications</i> , 2000 , 268, 607-11	3.4	120
202	Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. <i>Acta Neuropathologica</i> , 2017 , 133, 629-644	14.3	115
201	Comprehensive allelotype and genetic analysis of 466 human nervous system tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , 2000 , 59, 544-58	3.1	114
200	Acute Stroke in Times of the COVID-19 Pandemic: A Multicenter Study. <i>Stroke</i> , 2020 , 51, 2224-2227	6.7	110
199	Pathway inhibition: emerging molecular targets for treating glioblastoma. <i>Neuro-Oncology</i> , 2011 , 13, 566-79	1	104
198	The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells. <i>PLoS ONE</i> , 2011 , 6, e19823	3.7	104
197	Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. <i>Acta Neuropathologica</i> , 2018 , 136, 273-291	14.3	99
196	Nanosensor detection of an immunoregulatory tryptophan influx/kynurenine efflux cycle. <i>PLoS Biology</i> , 2007 , 5, e257	9.7	99
195	Costimulatory protein 41gB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness. <i>Clinical Cancer Research</i> , 2012 , 18, 105-17	12.9	91
194	The endogenous tryptophan metabolite and NAD ⁺ precursor quinolinic acid confers resistance of gliomas to oxidative stress. <i>Cancer Research</i> , 2013 , 73, 3225-34	10.1	90

193	A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma. <i>Clinical Cancer Research</i> , 2014 , 20, 6304-13	12.9	89
192	Processing of immunosuppressive pro-TGF-beta 1,2 by human glioblastoma cells involves cytoplasmic and secreted furin-like proteases. <i>Journal of Immunology</i> , 2001 , 166, 7238-43	5.3	87
191	Vaccine-based immunotherapeutic approaches to gliomas and beyond. <i>Nature Reviews Neurology</i> , 2017 , 13, 363-374	15	82
190	Ezrin-dependent promotion of glioma cell clonogenicity, motility, and invasion mediated by BCL-2 and transforming growth factor-beta2. <i>Journal of Neuroscience</i> , 2001 , 21, 3360-8	6.6	80
189	Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. <i>Neuro-Oncology</i> , 2016 , 18, 1529-1537	1	80
188	Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non-Small Cell Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 198, 777-787	10.2	79
187	The therapeutic potential of targeting tryptophan catabolism in cancer. <i>British Journal of Cancer</i> , 2020 , 122, 30-44	8.7	79
186	IMMU-54. THE ONCOMETABOLITE R-2-HYDROXYGLUTARATE SUPPRESSES THE INNATE IMMUNE MICROENVIRONMENT OF IDH1-MUTATED GLIOMAS VIA ARYL HYDROCARBON RECEPTOR SIGNALING. <i>Neuro-Oncology</i> , 2018 , 20, vi133-vi133	1	78
185	Iron Induces Anti-tumor Activity in Tumor-Associated Macrophages. <i>Frontiers in Immunology</i> , 2017 , 8, 1479	8.4	77
184	Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082). <i>Clinical Cancer Research</i> , 2016 , 22, 4797-4806	12.9	77
183	N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits transforming growth factor-beta release and reduces migration and invasiveness of human malignant glioma cells. <i>International Journal of Cancer</i> , 2001 , 93, 53-61	7.5	74
182	Sarcoma classification by DNA methylation profiling. <i>Nature Communications</i> , 2021 , 12, 498	17.4	74
181	In vivo nanoparticle imaging of innate immune cells can serve as a marker of disease severity in a model of multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 13227-13232	11.5	69
180	A vaccine targeting mutant IDH1 in newly diagnosed glioma. <i>Nature</i> , 2021 , 592, 463-468	50.4	68
179	Immature mesenchymal stem cell-like pericytes as mediators of immunosuppression in human malignant glioma. <i>Journal of Neuroimmunology</i> , 2013 , 265, 106-16	3.5	67
178	Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. <i>Neuro-Oncology</i> , 2013 , 15, 1017-26	1	65
177	A novel tool to analyze MRI recurrence patterns in glioblastoma. <i>Neuro-Oncology</i> , 2008 , 10, 1019-24	1	63
176	Tweety-Homolog 1 Drives Brain Colonization of Gliomas. <i>Journal of Neuroscience</i> , 2017 , 37, 6837-6850	6.6	62

175	Bevacizumab does not increase the risk of remote relapse in malignant glioma. <i>Annals of Neurology</i> , 2011 , 69, 586-92	9.4	62
174	Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. <i>Neuro-Oncology</i> , 2014 , 16, 1630-8	18	59
173	Neurological sequelae of cancer immunotherapies and targeted therapies. <i>Lancet Oncology</i> , 2016 , 17, e529-e541	21.7	59
172	Macrophage migration inhibitory factor (MIF) expression in human malignant gliomas contributes to immune escape and tumour progression. <i>Acta Neuropathologica</i> , 2011 , 122, 353-65	14.3	58
171	Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas. <i>Nature Communications</i> , 2020 , 11, 931	17.4	57
170	N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. <i>Neuro-Oncology</i> , 2019 , 21, 95-105	1	55
169	Decreased utilization of mental health emergency service during the COVID-19 pandemic. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021 , 271, 377-379	5.1	53
168	Clonally Expanded B Cells in Multiple Sclerosis Bind EBV EBNA1 and GialCAM.. <i>Nature</i> , 2022 ,	50.4	51
167	Structural Basis for Aryl Hydrocarbon Receptor-Mediated Gene Activation. <i>Structure</i> , 2017 , 25, 1025-1033.e3	3.3	50
166	K27M-mutant histone-3 as a novel target for glioma immunotherapy. <i>Oncotmunology</i> , 2017 , 6, e13283402	402	47
165	A suppressive oligodeoxynucleotide enhances the efficacy of myelin cocktail/IL-4-tolerizing DNA vaccination and treats autoimmune disease. <i>Journal of Immunology</i> , 2005 , 175, 6226-34	5.3	46
164	Accumulation of an endogenous tryptophan-derived metabolite in colorectal and breast cancers. <i>PLoS ONE</i> , 2015 , 10, e0122046	3.7	45
163	Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. <i>Neuro-Oncology</i> , 2013 , 15, 1405-12	1	45
162	Current status and future directions of anti-angiogenic therapy for gliomas. <i>Neuro-Oncology</i> , 2016 , 18, 315-28	1	44
161	Mouse mesenchymal stem cells suppress antigen-specific TH cell immunity independent of indoleamine 2,3-dioxygenase 1 (IDO1). <i>Stem Cells and Development</i> , 2010 , 19, 657-68	4.4	43
160	Dietary tryptophan links encephalogenicity of autoreactive T cells with gut microbial ecology. <i>Nature Communications</i> , 2019 , 10, 4877	17.4	41
159	Protein kinase C δ as a therapeutic target stabilizing blood-brain barrier disruption in experimental autoimmune encephalomyelitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 14735-40	11.5	41
158	Concepts in glioma immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2016 , 65, 1269-75	7.4	40

157	Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway. <i>Glia</i> , 2015 , 63, 78-90	9	39
156	Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial-study protocol. <i>BMJ Open</i> , 2016 , 6, e010956	3	38
155	Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus. <i>Neuro-Oncology</i> , 2019 , 21, 837-853	1	37
154	Tryptophan-2,3-dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor-4. <i>Journal of Neurochemistry</i> , 2016 , 136, 1142-1154	6	37
153	Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation. <i>Neuro-Oncology</i> , 2018 , 20, 367-379	1	35
152	Promotion of glioblastoma cell motility by enhancer of zeste homolog 2 (EZH2) is mediated by AXL receptor kinase. <i>PLoS ONE</i> , 2012 , 7, e47663	3.7	35
151	Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma. <i>Oncotarget</i> , 2015 , 6, 31050-68	3.3	35
150	The stress kinase GCN2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas. <i>Oncolmunology</i> , 2016 , 5, e1240858	7.2	34
149	EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2001-2001	2.2	34
148	Microenvironmental clues for glioma immunotherapy. <i>Current Neurology and Neuroscience Reports</i> , 2014 , 14, 440	6.6	33
147	Upregulation of tryptophanyl-tRNA synthetase adapts human cancer cells to nutritional stress caused by tryptophan degradation. <i>Oncolmunology</i> , 2018 , 7, e1486353	7.2	33
146	Tryptophan-2,3-Dioxygenase (TDO) deficiency is associated with subclinical neuroprotection in a mouse model of multiple sclerosis. <i>Scientific Reports</i> , 2017 , 7, 41271	4.9	32
145	Primary glioblastoma cultures: can profiling of stem cell markers predict radiotherapy sensitivity?. <i>Journal of Neurochemistry</i> , 2014 , 131, 251-64	6	29
144	Suppression of human CD4+ T cell activation by 3,4-dimethoxycinnamonyl-anthranilic acid (tranilast) is mediated by CXCL9 and CXCL10. <i>Biochemical Pharmacology</i> , 2011 , 82, 632-41	6	28
143	Correlated magnetic resonance imaging and ultramicroscopy (MR-UM) is a tool kit to assess the dynamics of glioma angiogenesis. <i>ELife</i> , 2016 , 5, e11712	8.9	28
142	Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. <i>Neuro-Oncology</i> , 2021 , 23, 356-375	1	28
141	Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot study. <i>Neuro-Oncology</i> , 2018 , 20, 826-837	1	27
140	Proximity ligation assay evaluates IDH1R132H presentation in gliomas. <i>Journal of Clinical Investigation</i> , 2015 , 125, 593-606	15.9	27

139	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. <i>Molecular and Cellular Proteomics</i> , 2019 , 18, 1255-1268	7.6	26
138	Fourier Transform Infrared Microscopy Enables Guidance of Automated Mass Spectrometry Imaging to Predefined Tissue Morphologies. <i>Scientific Reports</i> , 2018 , 8, 313	4.9	26
137	Involvement of protein kinase Cdelta and extracellular signal-regulated kinase-2 in the suppression of microglial inducible nitric oxide synthase expression by N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast). <i>Biochemical Pharmacology</i> , 2003 , 66, 1263-70	6	26
136	Diffusion-weighted MRI in transient global amnesia and its diagnostic implications. <i>Neurology</i> , 2020 , 95, e206-e212	6.5	25
135	Glioblastoma in elderly patients: solid conclusions built on shifting sand?. <i>Neuro-Oncology</i> , 2018 , 20, 174-183		24
134	Understanding and targeting alkylator resistance in glioblastoma. <i>Cancer Discovery</i> , 2014 , 4, 1120-2	24.4	23
133	CMV infection and glioma, a highly controversial concept struggling in the clinical arena. <i>Neuro-Oncology</i> , 2014 , 16, 332-3	1	23
132	Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib. <i>Clinical Cancer Research</i> , 2019 , 25, 253-265	12.9	23
131	Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma. <i>Neuro-Oncology</i> , 2020 , 22, 1162-1172	1	22
130	Does age matter? - A MRI study on peritumoral edema in newly diagnosed primary glioblastoma. <i>BMC Cancer</i> , 2011 , 11, 127	4.8	21
129	Shaping the glioma immune microenvironment through tryptophan metabolism. <i>CNS Oncology</i> , 2012 , 1, 99-106	4	21
128	Geriatric neuro-oncology: from mythology to biology. <i>Current Opinion in Neurology</i> , 2011 , 24, 599-604	7.1	20
127	Mutant IDH1: An immunotherapeutic target in tumors. <i>Oncolimmunology</i> , 2014 , 3, e974392	7.2	19
126	The aryl hydrocarbon receptor in tumor immunity. <i>Oncolimmunology</i> , 2012 , 1, 396-397	7.2	19
125	Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. <i>Acta Neuropathologica Communications</i> , 2019 , 7, 163	7.3	18
124	Cancer immunotherapy: exploiting neoepitopes. <i>Cell Research</i> , 2015 , 25, 887-8	24.7	18
123	N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) suppresses microglial inducible nitric oxide synthase (iNOS) expression and activity induced by interferon-gamma (IFN-gamma). <i>British Journal of Pharmacology</i> , 2001 , 134, 1279-84	8.6	18
122	Slowing down glioblastoma progression in mice by running or the anti-malarial drug dihydroartemisinin? Induction of oxidative stress in murine glioblastoma therapy. <i>Oncotarget</i> , 2016 , 7, 56713-56725	3.3	18

121	Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer. <i>OncImmunology</i> , 2017 , 6, e1274477	7.2	17
120	Treatment of anaplastic glioma. <i>Cancer Treatment and Research</i> , 2015 , 163, 89-101	3.5	17
119	Concepts for Immunotherapies in Gliomas. <i>Seminars in Neurology</i> , 2018 , 38, 62-72	3.2	17
118	Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas.. <i>Nature Cancer</i> , 2021 , 2, 723-740	15.4	17
117	Constitutive Expression of the Immunosuppressive Tryptophan Dioxygenase TDO2 in Glioblastoma Is Driven by the Transcription Factor C/EBP β <i>Frontiers in Immunology</i> , 2020 , 11, 657	8.4	16
116	Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio. <i>Neuro-Oncology</i> , 2018 , 20, 557-566	1	16
115	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. <i>Molecular and Cellular Proteomics</i> , 2018 , 17, 2132-2145	7.6	16
114	Synovial Fibroblasts Selectively Suppress Th1 Cell Responses through IDO1-Mediated Tryptophan Catabolism. <i>Journal of Immunology</i> , 2017 , 198, 3109-3117	5.3	15
113	Suppression of Th1 differentiation by tryptophan supplementation in vivo. <i>Amino Acids</i> , 2017 , 49, 1169-1175	3.75	15
112	Increasing the sensitivity of MRI for the detection of multiple sclerosis lesions by long axial coverage of the spinal cord: a prospective study in 119 patients. <i>Journal of Neurology</i> , 2017 , 264, 341-349	5.5	15
111	Monitoring innate immune cell dynamics in the glioma microenvironment by magnetic resonance imaging and multiphoton microscopy (MR-MPM). <i>Theranostics</i> , 2020 , 10, 1873-1883	12.1	15
110	Characterization of Contrast-Enhancing and Non-contrast-enhancing Multiple Sclerosis Lesions Using Susceptibility-Weighted Imaging. <i>Frontiers in Neurology</i> , 2019 , 10, 1082	4.1	15
109	A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2001-2001	2.2	15
108	Prognostic relevance of miRNA-155 methylation in anaplastic glioma. <i>Oncotarget</i> , 2016 , 7, 82028-82045	3.3	15
107	General control non-derepressible 2 (GCN2) in T cells controls disease progression of autoimmune neuroinflammation. <i>Journal of Neuroimmunology</i> , 2016 , 297, 117-26	3.5	15
106	Temporal evolution of acute multiple sclerosis lesions on serial sodium (Na) MRI. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 29, 48-54	4	14
105	Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma. <i>Molecular Cancer Research</i> , 2018 , 16, 767-776	6.6	14
104	Defective p53 antiangiogenic signaling in glioblastoma. <i>Neuro-Oncology</i> , 2010 , 12, 894-907	1	14

103	Understanding and Treating Glioblastoma. <i>Neurologic Clinics</i> , 2018 , 36, 485-499	4.5	12
102	INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies. <i>BMC Cancer</i> , 2020 , 20, 523	4.8	11
101	Phase II part of EORTC study 26101: The sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2019-2019	2.2	11
100	Systematic review of combinations of targeted or immunotherapy in advanced solid tumors 2021 , 9,		11
99	Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas. <i>Acta Neuropathologica</i> , 2017 , 133, 325-327	14.3	10
98	The promises of immunotherapy in gliomas. <i>Current Opinion in Neurology</i> , 2017 , 30, 650-658	7.1	10
97	EGFRvIII vaccine in glioblastoma-InACT-IVE or not ReACTive enough?. <i>Neuro-Oncology</i> , 2017 , 19, 1425-1426		10
96	Correlated MRI and Ultramicroscopy (MR-UM) of Brain Tumors Reveals Vast Heterogeneity of Tumor Infiltration and Neoangiogenesis in Preclinical Models and Human Disease. <i>Frontiers in Neuroscience</i> , 2018 , 12, 1004	5.1	10
95	Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma. <i>Journal of Neuro-Oncology</i> , 2014 , 117, 85-92	4.8	10
94	Radiation therapy and concurrent plus adjuvant temsirolimus (CCI-779) versus chemoradiation with temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2003-2003	2.2	10
93	Tryptophan metabolism in brain tumors - IDO and beyond. <i>Current Opinion in Immunology</i> , 2021 , 70, 57-66	6.8	10
92	Diffusion-weighted imaging of the dentate nucleus after repeated application of gadolinium-based contrast agents in multiple sclerosis. <i>Magnetic Resonance Imaging</i> , 2019 , 58, 1-5	3.3	10
91	Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas. <i>Current Opinion in Oncology</i> , 2018 , 30, 368-374	4.2	10
90	Uncompleted emergency department care and discharge against medical advice in patients with neurological complaints: a chart review. <i>BMC Emergency Medicine</i> , 2019 , 19, 52	2.4	9
89	Challenging cytomegalovirus data in glioblastoma. <i>Neuro-Oncology</i> , 2014 , 16, 165	1	9
88	Interaction between the heart and the brain in transient global amnesia. <i>Journal of Neurology</i> , 2019 , 266, 3048-3057	5.5	8
87	Good maths is needed to understand CMV data in glioblastoma. <i>International Journal of Cancer</i> , 2014 , 134, 2991-2	7.5	8
86	Abstract 4454: Identification of BAY-218, a potent and selective small-molecule AhR inhibitor, as a new modality to counteract tumor immunosuppression 2019 ,		8

85	Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3839-3852	2.2	8
84	Spatiotemporal evolution of venous narrowing in acute MS lesions. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018 , 5, e440	9.1	7
83	Vaccine Strategies in Gliomas. <i>Current Treatment Options in Neurology</i> , 2018 , 20, 11	4.4	7
82	Autoantigen-specific immunosuppression with tolerogenic peripheral blood cells prevents relapses in a mouse model of relapsing-remitting multiple sclerosis. <i>Journal of Translational Medicine</i> , 2016 , 14, 99	8.5	7
81	Anti-inflammatory strategies for the treatment of multiple sclerosis tryptophan catabolites may hold the key. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2006 , 3, 401-408		7
80	cMyc and ERK activity are associated with resistance to ALK inhibitory treatment in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2020 , 146, 9-23	4.8	7
79	Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes. <i>Cancer Medicine</i> , 2020 , 9, 8373-8385	4.8	7
78	Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial. <i>Radiology</i> , 2020 , 297, 164-175	20.5	7
77	MRI of Iron Oxide Nanoparticles and Myeloperoxidase Activity Links Inflammation to Brain Edema in Experimental Cerebral Malaria. <i>Radiology</i> , 2019 , 290, 359-367	20.5	7
76	Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study. <i>Neurology</i> , 2019 , 92, e2754-e2763	6.5	6
75	Lack of T1 hyperintensity in the dentate nucleus after 15 administrations of a macrocyclic contrast agent in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, 324-326	5.5	6
74	Blood-brain barrier and brain edema. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2012 , 104, 53-62	3	6
73	Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort study. <i>The Lancet Digital Health</i> , 2021 , 3, e784-e794	14.4	6
72	Susceptibility-weighted imaging in malignant melanoma brain metastasis. <i>Journal of Magnetic Resonance Imaging</i> , 2019 , 50, 1251-1259	5.6	5
71	Toxicity of teriflunomide in aryl hydrocarbon receptor deficient mice. <i>Biochemical Pharmacology</i> , 2015 , 98, 484-92	6	5
70	-CD40 Crosstalk in Glioblastoma Invasion and Temozolomide Resistance. <i>Frontiers in Oncology</i> , 2020 , 10, 747	5.3	5
69	Single-Cell High-Throughput Technologies in Cerebrospinal Fluid Research and Diagnostics. <i>Frontiers in Immunology</i> , 2019 , 10, 1302	8.4	5
68	Functional MHC class II is upregulated in neurofibromin-deficient Schwann cells. <i>Journal of Investigative Dermatology</i> , 2013 , 133, 1372-5	4.3	5

67	A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS2082-TPS2082	2.2	5
66	Autoimmune diseases and immunosuppressive therapy in relation to the risk of glioma. <i>Cancer Medicine</i> , 2020 , 9, 1263-1275	4.8	5
65	Normal mast cell numbers in the tissues of AhR-deficient mice. <i>Experimental Dermatology</i> , 2016 , 25, 62-34		5
64	Driving mesenchymal transition in glioblastoma. <i>Neuro-Oncology</i> , 2020 , 22, 1-2	1	5
63	Association of iron rim lesions with brain and cervical cord volume in relapsing multiple sclerosis. <i>European Radiology</i> , 2021 , 1	8	5
62	How to integrate immunotherapy into standard of care in glioblastoma. <i>Neuro-Oncology</i> , 2019 , 21, 699-700		4
61	Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial. <i>Neuro-Oncology</i> , 2020 , 22, 1667-1676	1	4
60	Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma. <i>Journal of Neuro-Oncology</i> , 2016 , 129, 533-539	4.8	4
59	Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation Neuro Master Match (NMM).. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS2084-TPS2084	2.2	4
58	Large-scale characterization of the microvascular geometry in development and disease by tissue clearing and quantitative ultramicroscopy. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021 , 41, 1536-1546 ⁴	7.3	4
57	TCR validation toward gene therapy for cancer. <i>Methods in Enzymology</i> , 2019 , 629, 419-441	1.7	4
56	Brain Atrophy in Natalizumab-treated Patients with Multiple Sclerosis: A 5-year Retrospective Study. <i>Journal of Neuroimaging</i> , 2019 , 29, 190-192	2.8	4
55	Venous Diameter Changes in Chronic Active Multiple Sclerosis Lesions. <i>Journal of Neuroimaging</i> , 2021 , 31, 394-400	2.8	4
54	Hypoxia Routes Tryptophan Homeostasis Towards Increased Tryptamine Production. <i>Frontiers in Immunology</i> , 2021 , 12, 590532	8.4	4
53	Central retinal artery occlusion as a neuro-ophthalmological emergency: the need to raise public awareness. <i>European Journal of Neurology</i> , 2021 , 28, 2111-2114	6	4
52	Nonmeasurable Speckled Contrast-Enhancing Lesions Appearing During Course of Disease Are Associated With IDH Mutation in High-Grade Astrocytoma Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 102, 1472-1480	4	4
51	Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. <i>Clinical Cancer Research</i> , 2021 ,	12.9	4
50	Synergy of vaccination and agonist OX40 treatment-toward a mechanism-driven combination of glioma immunotherapy. <i>Neuro-Oncology</i> , 2018 , 20, 4-5	1	3

49	Long-term dynamics of multiple sclerosis iron rim lesions.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 57, 103340	4	3
48	Investigation of the "central vein sign" in infratentorial multiple sclerosis lesions. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 45, 102409	4	3
47	Quantitative MRI texture analysis in chronic active multiple sclerosis lesions. <i>Magnetic Resonance Imaging</i> , 2021 , 79, 97-102	3.3	3
46	Chronobiology of transient global amnesia. <i>Journal of Neurology</i> , 2021 , 1	5.5	3
45	Comparing Expert and Non-Expert Assessment of Patients Presenting with Neurological Symptoms to the Emergency Department: A Retrospective Observational Study. <i>Neuropsychiatric Disease and Treatment</i> , 2020 , 16, 447-456	3.1	2
44	Molecular profiling-based decision for targeted therapies in wild-type glioblastoma. <i>Neuro-Oncology Advances</i> , 2020 , 2, vdz060	0.9	2
43	HIV-Associated Cerebellar Dysfunction and Improvement with Aminopyridine Therapy: A Case Report. <i>Case Reports in Neurology</i> , 2017 , 9, 121-126	1	2
42	VXM01 phase I study in patients with resectable progression of a glioblastoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2061-2061	2.2	2
41	Adding Papillomacular Bundle Measurements to Standard Optical Coherence Tomography Does Not Increase Sensitivity to Detect Prior Optic Neuritis in Patients with Multiple Sclerosis. <i>PLoS ONE</i> , 2016 , 11, e0155322	3.7	2
40	Hepatocyte-intrinsic type I interferon signaling reprograms metabolism and reveals a novel compensatory mechanism of the tryptophan-kynurenine pathway in viral hepatitis. <i>PLoS Pathogens</i> , 2020 , 16, e1008973	7.6	2
39	Integrated phospho-proteogenomic and single-cell transcriptomic analysis of meningiomas establishes robust subtyping and reveals subtype-specific immune invasion		2
38	Sex-related differences in stressful events precipitating transient global amnesia - A retrospective observational study. <i>Journal of the Neurological Sciences</i> , 2021 , 425, 117464	3.2	2
37	High-throughput discovery of cancer-targeting TCRs. <i>Methods in Enzymology</i> , 2019 , 629, 401-417	1.7	2
36	Activity-regulated cytoskeleton-associated protein/activity-regulated gene 3.1 (Arc/Arg3.1) enhances dendritic cell vaccination in experimental melanoma. <i>Oncoimmunology</i> , 2021 , 10, 1920739	7.2	2
35	MRI predictors for the conversion from contrast-enhancing to iron rim multiple sclerosis lesions.. <i>Journal of Neurology</i> , 2022 , 1	5.5	2
34	Off-label use of IV t-PA in patients with intracranial neoplasm and cavernoma. <i>Therapeutic Advances in Neurological Disorders</i> , 2018 , 11, 1756285617753423	6.6	1
33	Moderne Therapiestrategien bei hirneigenen glialen Tumoren. <i>InFo Neurologie & Psychiatrie</i> , 2013 , 15, 38-51	0	1
32	The current landscape of immunotherapy for pediatric brain tumors.. <i>Nature Cancer</i> , 2022 , 3, 11-24	15.4	1

31	MGMT promoter methylation as a predictive biomarker for response to radiotherapy versus chemotherapy in malignant astrocytomas in the elderly: The NOA-08 trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2000-2000	2.2	1
30	Mapping the Multiple Myeloma T Cell Landscape By Immunotherapeutic Perturbation Reveals Mechanism and Determinants of Response to Bispecific T Cell Engagers. <i>Blood</i> , 2021 , 138, 731-731	2.2	1
29	Fulminant Cytotoxic Edema in a Patient with Pneumococcal Meningoencephalitis. <i>Journal of Clinical Neurology (Korea)</i> , 2019 , 15, 575-577	1.7	1
28	Changes in Demographic and Diagnostic Spectra of Patients with Neurological Symptoms Presenting to an Emergency Department During the COVID-19 Pandemic: A Retrospective Cohort Study. <i>Neuropsychiatric Disease and Treatment</i> , 2020 , 16, 2221-2227	3.1	1
27	Susceptibility-Weighted 3T MRI of the Swallow Tail Sign in Multiple Sclerosis: A Case Control Study. <i>Journal of Neuroimaging</i> , 2020 , 30, 766-768	2.8	1
26	Diffusely appearing white matter in multiple sclerosis: Insights from sodium (Na) MRI. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 49, 102752	4	1
25	Impaired semantic memory during acute transient global amnesia. <i>Journal of Neuropsychology</i> , 2021 ,	2.6	1
24	Characterization of chronic active multiple sclerosis lesions with sodium (Na) magnetic resonance imaging-preliminary observations. <i>European Journal of Neurology</i> , 2021 , 28, 2392-2395	6	1
23	Highlights in Central Nervous System Tumors. <i>JAMA Oncology</i> , 2016 , 2, 1535-1536	13.4	1
22	Acute Corticonuclear Tract Ischemic Stroke with Isolated Central Facial Palsy. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2019 , 28, 495-498	2.8	1
21	A Set of Cell Lines Derived from a Genetic Murine Glioblastoma Model Recapitulates Molecular and Morphological Characteristics of Human Tumors. <i>Cancers</i> , 2021 , 13,	6.6	1
20	Intrathecal activation of CD8 memory T cells in IgG4-related disease of the brain parenchyma. <i>EMBO Molecular Medicine</i> , 2021 , 13, e13953	12	1
19	Tryptophan metabolism is inversely regulated in the tumor and blood of patients with glioblastoma. <i>Theranostics</i> , 2021 , 11, 9217-9233	12.1	1
18	Consistency of the "central vein sign" in chronic multiple sclerosis lesions.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 58, 103530	4	0
17	Decreased admissions and change in arrival mode in patients with cerebrovascular events during the first surge of the COVID-19 pandemic. <i>Neurological Research and Practice</i> , 2020 , 2, 47	3.2	0
16	MRI topography of lesions related to internuclear ophthalmoplegia in patients with multiple sclerosis or ischemic stroke. <i>Journal of Neuroimaging</i> , 2021 , 31, 471-474	2.8	0
15	Vergleichbare Effekte auf das Gesamtberleben. <i>InFo Neurologie & Psychiatrie</i> , 2021 , 23, 18-18	0	0
14	Comparative evaluation of T-cell receptors in experimental glioma-draining lymph nodes. <i>Neuro-Oncology Advances</i> , 2021 , 3, vdab147	0.9	0

- | | | | |
|----|--|-----|---|
| 13 | The remains of the day: neuropsychological findings in postacute transient global amnesia.. <i>Journal of Neurology</i> , 2022 , 1 | 5.5 | 0 |
| 12 | Immunotherapy of Gliomas 2018 , 657-664 | | |
| 11 | Aryl hydrocarbon receptor (AhR) regulation of inflammation and cancer. <i>Toxicology Letters</i> , 2013 , 221, S29 | 4.4 | |
| 10 | Immuntherapien bei Gliomen. <i>Onkologe</i> , 2017 , 23, 831-837 | 0.1 | |
| 9 | A3.18 Synovial Fibroblasts Inhibit Inflammatory T Cell Responses through Tryptophan Metabolism. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A20.1-A20 | 2.4 | |
| 8 | Moderne Therapiestrategien bei hirneigenen glialen Tumoren. <i>Info Onkologie</i> , 2013 , 16, 32-43 | | |
| 7 | Therapie primärer ZNS-Lymphome. <i>Onkopipeline</i> , 2009 , 2, 2-10 | | |
| 6 | Tumorprogress versus therapieinduzierte Veränderungen (Pseudoprogression) bei malignen Astrozytomen. <i>Onkopipeline</i> , 2009 , 2, 16-18 | | |
| 5 | IMMU-04. UNVEILING THE TUMOR-METABOLOME-IMMUNITY AXIS OF GLIOMA. <i>Neuro-Oncology</i> , 2021 , 23, vi92-vi92 | 1 | |
| 4 | PATH-39. INTEGRATED MOLECULAR-MORPHOLOGICAL MENINGIOMA CLASSIFICATION: A MULTICENTER RETROSPECTIVE ANALYSIS, RETRO- AND PROSPECTIVELY VALIDATED. <i>Neuro-Oncology</i> , 2021 , 23, vi123-vi124 | 1 | |
| 3 | The use of a dedicated neurological triage system improves process times and resource utilization: a prospective observational study from an interdisciplinary emergency department. <i>Neurological Research and Practice</i> , 2019 , 1, 29 | 3.2 | |
| 2 | Effect of Glioma N-Myc downstream regulated gene 1 (NDRG1) on the tumor microenvironment.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11587-11587 | 2.2 | |
| 1 | Treatment standards for direct oral anticoagulants in patients with acute ischemic stroke and non-valvular atrial fibrillation: A survey among German stroke units.. <i>PLoS ONE</i> , 2022 , 17, e0264122 | 3.7 | |